Filtered By:
Source: Heart Rhythm

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 406 results found since Jan 2013.

Letter to the Editor — Clinical Phenotypes in AF Trials
Yang et  al1 conducted a retrospective study of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. Their findings did not support the first primary Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET 4) outcome.2 Clinical phenotypes of atrial fib rillation (AF) should be considered.
Source: Heart Rhythm - May 20, 2021 Category: Cardiology Authors: Norman C. Wang Tags: Letters to the Editor Source Type: research

Clinical phenotypes of patients with atrial fibrillation enrolled in randomized controlled trials:AFFIRM and EAST-AFNET 4
Yang et al. conducted a retrospective study of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial.1 Their findings did not support the first primary Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET 4) outcome.2 Clinical phenotypes of atrial fibrillation (AF) should be considered.
Source: Heart Rhythm - May 20, 2021 Category: Cardiology Authors: Norman C. Wang Source Type: research

Letter to the Editor —Clinical phenotypes in AF trials
Yang et  al1 conducted a retrospective study of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. Their findings did not support the first primary Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET 4) outcome.2 Clinical phenotypes of atrial fib rillation (AF) should be considered.
Source: Heart Rhythm - May 20, 2021 Category: Cardiology Authors: Norman C. Wang Tags: Letter to the Editor Source Type: research

Pericardial Effusion Requiring Intervention in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Prevalence, Predictors and Associated In-hospital Adverse Events from 17,700 Procedures in the United States
Left atrial appendage occlusion has shown promise in mitigating risk of stroke in selected patients with atrial fibrillation.
Source: Heart Rhythm - May 17, 2021 Category: Cardiology Authors: Muhammad Bilal Munir, Muhammad Zia Khan, Douglas Darden, Deepak Kumar Pasupula, Sudarshan Balla, Frederick T. Han, Ryan Reeves, Jonathan C. Hsu Source Type: research

The Combination of Coronary Sinus Ostial Atresia/Abnormality and a Small Persistent Left Superior Vena Cava - Opportunity for Left Ventricular Lead Implantation and Unrecognized Source of Thromboembolic Stroke
Coronary sinus (CS) ostial atresia/anomalies prevents access to the CS from the right atrium (RA) for left ventricular (LV) lead implantation. Some patients with CS ostial anomalies also have a small persistent left superior vena cava (sPLSVC).
Source: Heart Rhythm - May 7, 2021 Category: Cardiology Authors: Fengwei Zou, Seth J. Worley, Torkel Steen, Matthew McKillop, Santosh Padala, Susan O ’Donoghue, Basar Candemir, Khalil Kanjwal, Michael Kaufman, Sahar Mouram, Matthew Sellers, David Strouse, Athanasios Thomaides, Devi Nair, Cyrus A. Hadadi, Alexander Ku Source Type: research

The combination of coronary sinus ostial atresia/abnormalities and a small persistent left superior vena cava —Opportunity for left ventricular lead implantation and unrecognized source of thromboembolic stroke
Coronary sinus (CS) ostial atresia/abnormalities prevent access to the CS from the right atrium (RA) for left ventricular (LV) lead implantation. Some patients with CS ostial abnormalities also have a small persistent left superior vena cava (sPLSVC).
Source: Heart Rhythm - May 7, 2021 Category: Cardiology Authors: Fengwei Zou, Seth J. Worley, Torkel Steen, Matthew McKillop, Santosh Padala, Susan O ’Donoghue, Basar Candemir, Khalil Kanjwal, Michael Kaufman, Sahar Mouram, Matthew Sellers, David Strouse, Athanasios Thomaides, Devi Nair, Cyrus A. Hadadi, Alexander Ku Tags: Clinical Source Type: research

EP News: Clinical
Kar et  al (Circulation April 6, 2021;Epub ahead of print, PMID XXXX) evaluated the WATCHMAN FLX left atrial appendage (LAA) closure device in patients in whom oral anticoagulation is indicated but are candidates for a nonpharmaceutical alternative in a prospective multicenter study. The primary safety en d point was the occurrence of one of the following events: death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring cardiac surgery. The primary effectiveness end point was the incidence of effective LAA closure at 12-month follow-up.
Source: Heart Rhythm - May 3, 2021 Category: Cardiology Authors: N.A. Mark Estes Tags: EP News Source Type: research

Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer
A 76-year-old female with obesity, hypertension, persistent atrial fibrillation, and heart failure with preserved ejection fraction is started on ibrutinib 420 mg once daily for Waldenstrom ’s macroglobulinemia. Due to concern for drug-drug interactions, her amiodarone is decreased from 200 to 100 mg daily, and she is continued on metoprolol succinate 100 mg daily and apixaban 5 mg twice daily. She presents to the clinic one month later with extensive superficial ecchymoses, and her apixaban dose is reduced to 2.5 mg twice daily due to concerns that this may reflect the combined antiplatelet effects of ibrutinib and anti...
Source: Heart Rhythm - April 27, 2021 Category: Cardiology Authors: Shiv Bagga, Sourbha S. Dani, Bruce G. Hook, Anju Nohria, Sarju Ganatra Source Type: research

EP News: Quality Improvement and Outcomes: Defining and Measuring Atrial Fibrillation Quality Indicators in Canada
In 2016, the Working Group published an initial report identifying and defining priority QIs in 3 distinct categories: access to care, treatment, and outcomes (Can J Cardiol 2016;32:1566, PMID 27297003). An iterative process resulted in the selection of 3 priority QIs: (i) proportion of AF patients at high risk of stroke receiving an oral anticoagulant, (ii) annual rate of stroke, (iii) annual rate of major hemorrhage. A feasibility assessment followed, which determined that none of the QIs as defined could be adequately measured with existing data sources.
Source: Heart Rhythm - April 26, 2021 Category: Cardiology Authors: Roopinder K. Sandhu, Stephen B. Wilton, Anne Marie Smith, Paul Dorian Source Type: research

Anti-diabetic drugs for preventing atrial fibrillation: a new revolution?
Type 2 diabetes mellitus (DM) and atrial fibrillation (AF) are two of the great epidemics of our time. DM affects and estimated 8.5% of adults in the US1, and is associated with an increased risk of cardiovascular events, including AF.2 AF in turn affects an estimated up to 12.5% of adults over age 65 years in the US, decreases quality of life and increases the risks of heart failure, stroke and death 3,4. In 2015, the EMPA-REG OUTCOME randomized controlled trial (RCT), assessing a sodium glucose co-transporter 2 inhibitor (SGLT-2i), sparked interest in the therapeutic potential for oral anti-diabetic agents to reduce card...
Source: Heart Rhythm - April 7, 2021 Category: Cardiology Authors: William F. McIntyre, Jeff S. Healey Source Type: research

Antidiabetic drugs for preventing atrial fibrillation: A new revolution?
Type 2 diabetes mellitus (DM) and atrial fibrillation (AF) are 2 of the great epidemics of our time. DM affects an estimated 8.5% of adults in the United States1 and is associated with an increased risk of cardiovascular events, including AF.2 AF in turn affects up to an estimated 12.5% of adults older than 65 years in the United States, decreases quality of life, and increases the risks of heart failure, stroke, and death.3,4 In 2015, the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) randomized controlled trial (RCT), which assessed the sodium glucose c...
Source: Heart Rhythm - April 7, 2021 Category: Cardiology Authors: William F. McIntyre, Jeff S. Healey Tags: Editorial Commentary Source Type: research

Who is at risk of atrial fibrillation?
Atrial fibrillation (AF) is a common cause of stroke, with prevalence increasing alongside the aging of our population [1]. Increasing age, hypertension, obesity, heart failure, sleep apnea, diabetes, coronary disease, chronic kidney disease and smoking account for much of the global risk of AF [2 3]. Incident AF is also predicted by both rare and common genetic variants, many of which encode for cardiac structural and electrical proteins, as well as by more complex heritable traits such as height, obesity and race [4-6].
Source: Heart Rhythm - February 24, 2021 Category: Cardiology Authors: Jeff S. Healey, Jason D. Roberts, Thalia S. Field Source Type: research

Blood biomarkers to detect new-onset atrial fibrillation and cardioembolism in ischemic stroke patients
Accumulating data suggest blood biomarkers could inform stroke etiology.
Source: Heart Rhythm - February 6, 2021 Category: Cardiology Authors: Dorin Harpaz, Ram Bajpai, Geelyn J.L. Ng, Michael Soljak, Robert S. Marks, Christine Cheung, Thiruma Valavan Arumugam, Amy M.L. Quek, Alfred I.Y. Tok, Raymond C.S. Seet Source Type: research

Racial Differences in Incidence of Atrial Fibrillation after Cryptogenic Stroke
The incidence of atrial fibrillation (AF) is lower among non-whites compared to whites, despite a higher burden of AF risk factors. The incidence of new AF after cryptogenic stroke among minorities, however, is unknown.
Source: Heart Rhythm - January 29, 2021 Category: Cardiology Authors: David B. Laslett, Abdullah Haddad, Hardik Mangrolia, Dianna Gaballa, Olivia Follis, Chethan Gangireddy, Anuj Basil, Richard Greenberg, George Yesenosky, Edmond Cronin, Joshua Cooper, Isaac R. Whitman Source Type: research

Racial differences in the incidence of atrial fibrillation after cryptogenic stroke
The incidence of atrial fibrillation (AF) is lower in nonwhites than in whites despite a higher burden of AF risk factors. However, the incidence of new AF after cryptogenic stroke in minorities is unknown.
Source: Heart Rhythm - January 29, 2021 Category: Cardiology Authors: David B. Laslett, Abdullah Haddad, Hardik Mangrolia, Dianna Gaballa, Olivia Follis, Chethan Gangireddy, Anuj Basil, Richard Greenberg, George Yesenosky, Edmond Cronin, Joshua Cooper, Isaac R. Whitman Source Type: research